DarioHealth amends credit facility; resets covenants, waives Q2/Q3 tests, adds $10M liquidity covenant

DarioHealth Corp.

Credit agreement amended with Callodine Commercial Finance on Nov 5, 2025.
Financial covenant testing waived for Q2 and Q3 2025; minimum unencumbered liquid assets set at $10M.
Additional $2.5M funding from lenders now uncommitted and discretionary; exit fee increased by $150k.
Warrant exercise price reduced from $16.556 to $15.3495; conversion price on up to $2.5M loan reduced to $15.3495.
Amendment fee of $150k paid; 13-week cash-flow reporting required when liquidity below $11M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.